Notably, the findings emerging from our work revealed MMP-10 as a novel biomarker of SSc-ILD+, and its combination with MMP-7, MMP-9, and MMP-12 establishes a biomarker signature that significantly improves the ability to identify ILD in SSc patients. This evidence concerns the gene MMP7 and systemic sclerosis.